Cidara Therapeutics Gross Margin 2014-2022 | CDTX
Current and historical gross margin for Cidara Therapeutics (CDTX) over the last 10 years. The current gross profit margin for Cidara Therapeutics as of December 31, 2022 is %.
| Cidara Therapeutics Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2022-12-31 |
$0.06B |
$0.06B |
100.00% |
| 2022-09-30 |
$0.06B |
$0.06B |
100.00% |
| 2022-06-30 |
$0.03B |
$0.03B |
100.00% |
| 2022-03-31 |
$0.05B |
$0.05B |
100.00% |
| 2021-12-31 |
$0.05B |
$0.05B |
100.00% |
| 2021-09-30 |
$0.05B |
$0.05B |
100.00% |
| 2021-06-30 |
$0.04B |
$0.04B |
100.00% |
| 2021-03-31 |
$0.01B |
$0.01B |
100.00% |
| 2020-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2020-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2020-06-30 |
$0.03B |
$0.03B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.072B |
$0.064B |
|
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|
